DanielJoshuaGruskinMD

Clinical Biochemical Genetics, Clinical Genetics

Physician

Dr. Gruskin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Cedars-Sinai Medical CenterResidency, Medical Genetics and Genomics, 2000 - 2003
Louisiana State University School of MedicineResidency, Pediatrics, 1997 - 2000
Medical College of Georgia at Augusta UniversityClass of 1997

PubMed

23 citations
Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease.
Ozlem Goker-Alpan, Michael J. Gambello, Gustavo Maegawa, Khan Nedd, Daniel Gruskin
JIMD Reports. 2015-08-25
29 citations
Social-adaptive and psychological functioning of patients affected by Fabry disease
Dawn Laney, Daniel Gruskin, Paul M. Fernhoff, Joseph F. Cubells, Opal Y. Ousley
Journal of Inherited Metabolic Disease. 2010-01-20
219 citations
Early Treatment with Alglucosidase Alfa Prolongs Long Term Survival of Infants with Pompe Disease
Priya S. Kishnani, Deya Corzo, Nancy D. Leslie, Daniel Gruskin, Ans T. van der Ploeg
Pediatric Research. 2009-09-01

LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateAugust 15th, 2022
LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership AppointmentsMay 19th, 2021
LogicBio Therapeutics Receives FDA Fast Track Designation for LB-001 for the Treatment of Methylmalonic Acidemia (MMA)November 4th, 2020
Join now to see all